Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer~  * Stage IIIB disease that is ineligible for combined modality therapy OR~ * Stage IV disease~* Measurable disease~* No clinically detectable (by physical exam) third-space fluid collection (e.g., ascites or pleural effusions) that cannot be controlled by drainage or other procedures~* No brain metastases (even if treated)~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-1~Life expectancy:~* At least 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9 g/dL~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases present)~* Alkaline phosphatase no greater than 3 times ULN (5 times ULN if liver metastases present)~Renal:~* Creatinine clearance at least 45 mL/min~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to take folic acid or cyanocobalamin (vitamin B12) supplementation~* No uncontrolled infection~* No concurrent chronic debilitating disease~* No weight loss of 10% or more within the past 6 weeks~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic or genetic therapy for lung cancer~* No concurrent immunomodulating agents~Chemotherapy:~* No prior chemotherapy for lung cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy to a different site and recovered~* No prior radiotherapy to 25% or more of bone marrow~* No prior radiotherapy to whole pelvis~* No prior radiotherapy for primary disease~* No concurrent radiotherapy~Surgery:~* More than 4 weeks since prior major surgery~Other:~* No aspirin or nonsteroidal anti-inflammatory agents 2 days before, during, and for 2 days after pemetrexed disodium administration (5 days for long-acting agents such as piroxicam, naproxen, diflunisal, or nabumetone)~* No other concurrent cytostatic or cytotoxic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: pemetrexed + gemcitabine (Type: EXPERIMENTAL): Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
- Arm II: pemetrexed + gemcitabine (Type: EXPERIMENTAL): Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
- Arm III: pemetrexed + gemcitabine (Type: EXPERIMENTAL): Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete